RSAD2 Activators
The chemical class of RSAD2 Activators is characterized by a diverse set of compounds that indirectly influence the activation of RSAD2 through their action on various cellular signaling pathways. These chemicals target key components within these pathways, such as kinases, phosphatases, and transcription factors, thereby modulating the cellular environment and signaling mechanisms that ultimately lead to the activation of RSAD2. These compounds exert their effects by interacting with specific targets within the cell, which are integral to various signaling cascades. For instance, Tofacitinib, a JAK inhibitor, modulates the JAK-STAT pathway, which is critical for interferon signaling and subsequent RSAD2 activation. Similarly, CAL-101 and LY294002, both PI3K inhibitors, impact the PI3K/AKT pathway, influencing immune responses and interferon-mediated processes.
Other compounds in this class, such as Trametinib and Losmapimod, target the MEK/ERK and p38 MAPK pathways, respectively. These pathways are involved in cellular responses to external stimuli, including cytokines and stress signals, and their modulation can indirectly contribute to the activation of RSAD2. Additionally, compounds like Rapamycin and Wortmannin, which target mTOR and PI3K pathways, respectively, can induce changes in cellular metabolism and stress responses, influencing RSAD2 activation. Furthermore, chemicals like BAY 11-7082 and BMS-345541, which inhibit NF-kappaB and IKK, alter transcriptional responses within the cell, impacting the regulation of genes involved in the interferon signaling pathway. BX795, by inhibiting TBK1 and IKKε, affects IRF3-mediated pathways, a key aspect of interferon signaling. Lastly, Dasatinib, a broad-spectrum tyrosine kinase inhibitor, by modulating various tyrosine kinase-dependent pathways, influences multiple aspects of cellular signaling, including those related to interferon response and RSAD2 activation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
CAL-101, a selective PI3K inhibitor, impacts the PI3K/AKT pathway. This modulation can alter immune responses, thereby affecting interferon pathways and indirectly influencing RSAD2 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, another PI3K inhibitor, can modulate the PI3K/AKT pathway. By impacting this pathway, it affects downstream interferon signaling processes, thereby indirectly impacting RSAD2 activation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, affects the MEK/ERK pathway, which is involved in cellular responses to external stimuli. This modulation can influence interferon signaling, indirectly affecting RSAD2 activation. | ||||||
Losmapimod | 585543-15-3 | sc-489299 sc-489299A | 10 mg 50 mg | $228.00 $825.00 | ||
Losmapimod, a p38 MAPK inhibitor, affects the p38 MAPK pathway involved in stress and cytokine responses. Inhibiting this pathway can alter cellular responses, indirectly affecting RSAD2 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
This inhibitor specifically targets JNK within the MAPK pathway, involved in stress and cytokine responses. By modulating JNK activity, it indirectly influences RSAD2 activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, affects a key pathway in cell growth and metabolism. Its influence on mTOR can indirectly affect cellular stress responses, potentially influencing RSAD2 activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor affecting the PI3K/AKT pathway, thereby indirectly influencing cellular responses that are part of the interferon signaling cascade, potentially affecting RSAD2 activation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is a specific inhibitor of NF-kappaB, a crucial transcription factor in immune responses. By modulating NF-kappaB activity, it can indirectly influence the pathways leading to RSAD2 activation. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541 targets the IKK complex, affecting the NF-kappaB pathway. Since NF-kappaB is crucial in immune response regulation, modulating this pathway can indirectly influence RSAD2 activation. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX795 inhibits TBK1 and IKKε, key kinases in IRF3 activation. By inhibiting these kinases, BX795 can indirectly affect IRF3-mediated interferon signaling pathways, influencing RSAD2 activation. | ||||||